Artal Group’s Novavax NVAX Stock Holding History

Artal Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,000	Closed	-$940K	–	112
2018 Q3	$940K	Hold	25,000	–	–	0.02%	100
2018 Q2	$670K	Hold	25,000	–	–	0.01%	101
2018 Q1	$1.05M	Hold	25,000	–	–	0.01%	105
2017 Q4	$620K	Hold	25,000	–	–	0.01%	118
2017 Q3	$570K	Hold	25,000	–	–	0.01%	110
2017 Q2	$575K	Hold	25,000	–	–	0.01%	106
2017 Q1	$640K	Hold	25,000	–	–	0.01%	93
2016 Q4	$630K	Hold	25,000	–	–	0.01%	88
2016 Q3	$1.04M	Buy	+25,000	New	+$3.23M	0.02%	91

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artal Group's NVAX Position: Q4 2018 in Review

Artal Group sold out of Novavax (NVAX) in Q4 2018, closing a stake of 25,000 shares — an estimated $940K sold.

Artal Group first reported a position in NVAX in Q3 2016 and held it in 9 quarters. The position peaked at $1.05M in Q1 2018. 167 funds tracked by Wall St. Rank hold NVAX as of Q4 2018.

Artal Group reported no remaining Novavax position as of Q4 2018 after selling out during the quarter.
Artal Group sold 25,000 Novavax shares in Q4 2018, an estimated $940K.
Artal Group first reported a position in Novavax in Q3 2016 and held it in 9 quarters.
Artal Group's Novavax position peaked at $1.05M in Q1 2018.
167 funds tracked by Wall St. Rank held Novavax as of Q4 2018.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.